Investors & Media

Webcast ImageWebcast
Investor Webcast from ASH (Live)
12/05/16 at 12:15 p.m. PT
Investor Webcast from ASH
Monday, December 5, 2016 12:15 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
EHA 2016 Poster: GBT440, a Novel HbS Polymerization Inhibitor, Increases Hb Oxygen Affinity and Results in a Rapid Improvement in Hemolysis and Anemia
EHA 2016 Poster: Pharmacokinetics (PK) and Pharmacodynamics (PD) of GBT440, a Novel Hemoglobin S (HbS) Polymerization Inhibitor for the Treatment of Sickle Cell Disease (SCD), in Healthy Volunteers and SCD Patients
Corporate Profile
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is currently evaluating GBT440 in a Phase 1/2 study in both healthy subjects and adults with SCD and a Phase 2a study in adolescents with SCD. GBT is also investigating GBT440 for th... More >>
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$19.10
Change (%) Stock is Down 0.1 (0.52%)
Volume273,820
Data as of 12/02/16 4:00 p.m. ET
Refresh quote
Corporate Presentation
Download Documentation Corporate Presentation (November 2016)
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
12/04/16Global Blood Therapeutics Announces New Long-Term Clinical Data from Ongoing Phase 1/2 Trial of GBT440 in Sickle Cell Disease at ASH
--Results Showed GBT440 Treatment Led to Rapid, Significant, Profound and Durable Reduction in Hemolysis and Sickled Cells in All Patients Treated for Up to Six Months-- --Company to Host Webcast Tomorrow at 12:15 p.m. PT to Discuss Data-- SOUTH SAN FRANCISCO, Calif., Dec. 04, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of results from its ongoing Phase 1/2 GBT440-001 study that further support the safety and efficacy profile o... 
Printer Friendly Version
11/30/16Global Blood Therapeutics Announces Upcoming Investor Webcast to Review GBT440 Data Being Presented at ASH that Support Sickle Cell Disease Program
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced that it will host an investor webcast on Monday, December 5, 2016, at 12:15 p.m. PT/3:15 p.m. ET, to review new data being presented at the 58th American Society of Hematology (ASH) Annual Meeting & Exposition Conference in San Diego that support its GBT440 program in sickle cell disease (SCD). The investor event will feature members of GBT’s management team an... 
Printer Friendly Version
11/30/16Global Blood Therapeutics Announces GBT440 Granted Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced that the European Commission (EC), acting on a positive recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), has designated GBT440 as an orphan medicinal product for the treatment of sickle cell disease (SCD). "Receiving orphan designation from the EC marks a significant milestone both for the SCD co... 
Printer Friendly Version
11/28/16Global Blood Therapeutics Announces Initiation of Phase 2a Trial of GBT440 in Idiopathic Pulmonary Fibrosis (IPF)
SOUTH SAN FRANCISCO, Calif., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), today announced enrollment of the first patient in ZEPHYR, a Phase 2a clinical trial evaluating the safety and efficacy of GBT440 for the treatment of hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest. Hypoxemia (abnormally low levels of oxygen in the blood) is a common finding in IPF, is the underlying cause for patients’ sym... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
12/05/16 12:15 p.m. PT
Investor Webcast from ASH
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.